AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2024

May 31, 2024

30936_dirs_2024-05-31_59d1dd2a-b6ab-4d3a-9afa-80386d9c1dc6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2024-05-30

Reporting Person: Rommel Christian (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-30	Stock Option (Right to Buy)	$54.06	A	26000	Acquired	2034-05-30	Common Shares (26000)	Direct

Footnotes

F1: This option was granted on May 30, 2024 with respect to 26,000 Common Shares, with 100% of the shares vesting in 36 equal monthly installments beginning on June 30, 2024.